Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Cost analysis of group versus usual care in patients with type 2 diabetes in the ROMEO clinical trial.

Sicuro J, Bondonio P, Charrier L, Berchialla P, Cavallo F, Porta M, Trento M.

Nutr Metab Cardiovasc Dis. 2013 Feb;23(2):e13-4. doi: 10.1016/j.numecd.2012.11.005. Epub 2012 Dec 7. No abstract available.

PMID:
23220076
2.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
3.

Cost-effectiveness of insulin analogues for diabetes mellitus.

Cameron CG, Bennett HA.

CMAJ. 2009 Feb 17;180(4):400-7. doi: 10.1503/cmaj.081180.

4.

Managing the space between visits: a randomized trial of disease management for diabetes in a community health center.

Anderson DR, Christison-Lagay J, Villagra V, Liu H, Dziura J.

J Gen Intern Med. 2010 Oct;25(10):1116-22. doi: 10.1007/s11606-010-1419-5. Epub 2010 Jun 16.

5.

Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting.

Mittendorf T, Smith-Palmer J, Timlin L, Happich M, Goodall G.

Diabetes Obes Metab. 2009 Nov;11(11):1068-79. doi: 10.1111/j.1463-1326.2009.01099.x. Epub 2009 Sep 3.

PMID:
19732121
7.

Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of type 2 diabetes.

Caro JJ, Klittich WS, Raggio G, Kavanagh PL, O'Brien JA, Shomphe LA, Flegel KM, Copley-Merriman C, Sigler C.

Clin Ther. 2000 Jan;22(1):116-27.

PMID:
10688395
8.
10.

Cost-effectiveness and net benefit of enhanced treatment of depression for older adults with diabetes and depression.

Katon W, Unützer J, Fan MY, Williams JW Jr, Schoenbaum M, Lin EH, Hunkeler EM.

Diabetes Care. 2006 Feb;29(2):265-70.

PMID:
16443871
11.

Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results.

Jendle J, Torffvit O, Ridderstråle M, Ericsson Å, Nilsen B, Bøgelund M.

J Med Econ. 2012;15 Suppl 2:1-5. doi: 10.3111/13696998.2012.703633. Epub 2012 Aug 1.

PMID:
22853443
12.

Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus.

Maetzel A, Ruof J, Covington M, Wolf A.

Pharmacoeconomics. 2003;21(7):501-12.

PMID:
12696990
13.

Glycemic control with insulin glargine plus insulin glulisine versus premixed insulin analogues in real-world practices: a cost-effectiveness study with a randomized pragmatic trial design.

Levin PA, Zhang Q, Mersey JH, Lee FY, Bromberger LA, Bhushan M, Bhushan R.

Clin Ther. 2011 Jul;33(7):841-50. doi: 10.1016/j.clinthera.2011.05.091. Epub 2011 Jun 30.

PMID:
21719107
14.

Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland.

Brändle M, Erny-Albrecht KM, Goodall G, Spinas GA, Streit P, Valentine WJ.

Int J Clin Pharmacol Ther. 2009 Aug;47(8):501-15.

PMID:
19640359
15.

[Costs of therapy of insulin-treated patients with Diabetes mellitus in Germany. Results of the JEVIN trial].

Schiel R, Müller UA, Stein G.

Med Klin (Munich). 2005 Aug 15;100(8):453-61. German.

PMID:
16096726
16.

Estimating the direct cost of Type 2 diabetes in Greece: the effects of blood glucose regulation on patient cost.

Athanasakis K, Ollandezos M, Angeli A, Gregoriou A, Geitona M, Kyriopoulos J.

Diabet Med. 2010 Jun;27(6):679-84. doi: 10.1111/j.1464-5491.2010.03004.x.

PMID:
20546287
17.

Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden.

Smith-Palmer J, Fajardo-Montañana C, Pollock RF, Ericsson A, Valentine WJ.

J Med Econ. 2012;15(5):977-86. doi: 10.3111/13696998.2012.692340. Epub 2012 May 23.

PMID:
22563742
18.

Translating the Diabetes Control and Complications Trial (DCCT) into clinical practice: overcoming the barriers.

Zinman B.

Diabetologia. 1997 Jul;40 Suppl 2:S88-90. Review. No abstract available.

PMID:
9248707
19.
20.

Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin.

Malanda UL, Welschen LM, Riphagen II, Dekker JM, Nijpels G, Bot SD.

Cochrane Database Syst Rev. 2012 Jan 18;1:CD005060. doi: 10.1002/14651858.CD005060.pub3. Review.

PMID:
22258959

Supplemental Content

Support Center